MacroGenics, Inc.
MGNX · Price history
Price at last available close
$2.37
−$1.69 (-41.63%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About MacroGenics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
How they make money
MacroGenics is a biopharmaceutical company that generates revenue primarily through collaborative research and development agreements, which include upfront payments, milestone payments, and royalties from partners. The company also earns revenue from the sale of its commercial products and contract manufacturing services provided to third parties.
Products & services
MacroGenics develops and commercializes antibody-based therapeutics for the treatment of cancer, utilizing proprietary platforms such as DART and TRIDENT to create bispecific and multispecific molecules.
Brands & revenue mix
Proprietary bispecific antibody platform.
Separate brand revenue is not available in this research.Source
Proprietary multispecific antibody platform.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Disclosed major customers
- Gilead Sciences, Inc.Source
Customer concentration
For the year ended December 31, 2025, revenue from Gilead Sciences, Inc. accounted for a significant portion of the company's total revenue.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical and commercial drug supplies; specific supplier names are unnamed.Source
Business relationships & partnerships
- Gilead Sciences, Inc. — A strategic collaboration involving the licensing of preclinical programs and the development of antibody-based therapeutics.Source
Competitors
- Large pharmaceutical companies — Companies developing oncology therapeutics and bispecific antibody platforms that compete with MacroGenics' pipeline.Source
Strengths
- Proprietary antibody-based technology platforms (DART and TRIDENT)Source
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
24
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
29
Poor
Financial Strength
20
Business Quality / Moat
12
Management
60
Growth Quality
47
Risk / Durability
11
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
33
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
45/100
Building Historical Record
Model Score 45/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for MGNX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MGNX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can MGNX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is MGNX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for MGNX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify MGNX's current valuation?
Essential Investment Snapshot
Wall Street Score
24
Opportunity Score
33
Market Cap
$150.7M
P/E Ratio
-16.9
EPS
$-0.22
52-Week High
$5.08
52-Week Low
$1.29
Beta
1.23
Analyst Target
$6.00
Shares Outstanding
63.2M
Total Revenue
$167.7M
Total Debt
$35.1M
Dividend
No current dividend
Liquidation Value / Share
$0.68
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for MGNX
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-8.6x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on MGNX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary antibody-based technology platforms (DART and TRIDENT).
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on collaborative partners for development and commercialization success.
- −Uncertainty of clinical trial results and regulatory approval.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
24
Oct 1, 2026
Change
+0.1
points
Current Score
24
Oct 5, 2026
Category Changes
MGNX increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
25
Projected Change
+1.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 1.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$2.37
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $167.7M | $149.5M | $148.3M | $57.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $83.1M | $43.2M | $12.3M | $8.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $84.6M | $106.3M | $136.0M | $49.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $96.5M | $140.0M | $177.2M | $166.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $28.9M | $39.2M | $71.0M | $52.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $125.3M | $179.2M | $246.6M | $217.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$81.7M | -$59.6M | -$57.4M | $2.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$40.8M | -$72.8M | -$110.6M | -$168.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $16.9M | $8.5M | $1.1M | $1.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$104.5M | -$75.3M | -$66.0M | -$9.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$89.9M | -$672K | $944K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$14.6M | -$74.6M | -$67.0M | -$9.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.22 | $-1.18 | $-1.07 | $-0.15 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 63.59M | 63.16M | 62.62M | 61.93M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 63.59M | 63.16M | 62.62M | 61.93M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$32.8M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.31
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-67.4%
Cash Change
-12.8%
Margin Change
+222.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 47.6%. EPS declined 154.4%. Cash declined 12.8%. Total debt declined 67.4%. Net income margin improved by 222.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
Rumor Mill · MGNX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial